A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer
Status:
Active, not recruiting
Trial end date:
2026-02-23
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and efficacy of the combination of Avelumab, (a fully human
anti-programmed death ligand 1 (PD-L1) IgG1 antibody) in combination with a taxane
chemotherapy (docetaxel) in patients with metastatic urothelial cancer who are either
ineligible to receive cisplatin based chemotherapy, refractory to cisplatin in first line
setting or have disease relapse after receiving cisplatin based chemotherapy within a year in
the neoadjuvant or adjuvant setting.